公开(公告)号：US08992939B2

公开(公告)日：2015-03-31

申请号：US13280043

申请日：2011-10-24

Applicant: Gale Smith ,  Yingyun Wu ,  Michael Massare ,  Peter Pushko ,  Margret Nathan ,  Thomas Kort ,  Robin Robinson

Inventor： Gale Smith ,  Yingyun Wu ,  Michael Massare ,  Peter Pushko ,  Margret Nathan ,  Thomas Kort ,  Robin Robinson

IPC: C12N7/00 ,  C12N7/04 ,  A61K39/145 ,  A61K39/12 ,  C12N9/24 ,  A61K39/00

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55555 ,  C07K14/005 ,  C07K2319/01 ,  C07K2319/03 ,  C12N9/2402 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171 ,  C12N2760/16222 ,  C12N2760/16223 ,  C12N2760/16251 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20051 ,  C12N2800/22 ,  C12Y302/01018

Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Abstract translation: 本发明公开了一种增加包含表达禽流感基因蛋白质的病毒样颗粒的生产的方法。 本发明还包括制备和使用所述VLP的方法。

公开(公告)号：US20050009008A1

公开(公告)日：2005-01-13

申请号：US10617569

申请日：2003-07-11

Applicant: Robin Robinson ,  Peter Pushko

Inventor： Robin Robinson ,  Peter Pushko

IPC: A61K39/145 ,  C07H21/04 ,  C07K14/11 ,  C12N7/01 ,  C12N7/04 ,  C12Q1/70 ,  C12N15/09 ,  C12N15/70 ,  C12N15/74 ,  C07K17/00 ,  C07K14/00 ,  C12N15/87 ,  C07K1/00 ,  A61K39/12 ,  C12N15/63 ,  C12N15/85

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/575 ,  A61K2039/70 ,  C07H21/04 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

Abstract translation: 提供重组流感病毒蛋白，包括流行性感冒病毒，亚病毒颗粒，病毒样颗粒（VLP），VLP复合物和/或其任何部分作为流感病毒疫苗。 本发明基于两种疫苗技术的组合：（1）本质安全的重组疫苗技术，和（2）高度免疫原性的，自组装的蛋白质大分子，其包埋在质膜中，并且包含表现中和表位的流感病毒结构蛋白的多个拷贝 在原生构象。 更具体地说，本发明涉及由人流感病毒A型/悉尼/ 5/94（H3N2）和/或禽流感的重组结构蛋白构成的功能同型和异型重组流感病毒样颗粒（VLPs）的设计和生产 病毒A型/香港/ 1073/99（H9N2）在杆状病毒感染昆虫细胞中的应用，并将其作为疫苗用于预防流感感染和作为病毒结构研究和临床诊断的实验室试剂。

公开(公告)号：US20130039938A1

公开(公告)日：2013-02-14

申请号：US13280043

申请日：2011-10-24

Applicant: Gale SMITH ,  Yingyun Wu ,  Michael Massare ,  Peter Pushko ,  Margret Nathan ,  Thomas Kort ,  Robin Robinson

Inventor： Gale SMITH ,  Yingyun Wu ,  Michael Massare ,  Peter Pushko ,  Margret Nathan ,  Thomas Kort ,  Robin Robinson

IPC: A61K39/145 ,  C12P21/02 ,  C12N9/24 ,  C07K14/11 ,  A61P37/04

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55555 ,  C07K14/005 ,  C07K2319/01 ,  C07K2319/03 ,  C12N9/2402 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171 ,  C12N2760/16222 ,  C12N2760/16223 ,  C12N2760/16251 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20051 ,  C12N2800/22 ,  C12Y302/01018

Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

公开(公告)号：US20060263804A1

公开(公告)日：2006-11-23

申请号：US11372466

申请日：2006-03-10

Applicant: Robin Robinson ,  Peter Pushko

Inventor： Robin Robinson ,  Peter Pushko

IPC: C12Q1/68 ,  C12P21/06

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/575 ,  A61K2039/70 ,  C07H21/04 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

公开(公告)号：US08951537B2

公开(公告)日：2015-02-10

申请号：US13297125

申请日：2011-11-15

Applicant: Gale Smith ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

Inventor： Gale Smith ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

IPC: A61K39/145 ,  C12N7/00 ,  C12N7/04 ,  C07K14/005 ,  C12N15/86 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/14143 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Abstract translation: 本发明公开并要求从具有大流行潜力的病毒中表达和/或含有季节性流感病毒蛋白，禽流感病毒蛋白和/或流感病毒蛋白质的病毒样颗粒（VLPs）。 本发明包括包含所述蛋白质的载体构建体，包含所述构建体的细胞，制剂和包含本发明的VLP的疫苗。 本发明还包括制备和施用VLP到脊椎动物的方法，包括诱导季节性和禽流感的实质性免疫或其至少一种症状的方法。

公开(公告)号：US08795682B2

公开(公告)日：2014-08-05

申请号：US12598271

申请日：2008-05-02

Applicant: Richard W. Compans ,  Baozhong Wang ,  Beatrice Hahn ,  Weimin Liu ,  Gale Smith ,  Peter Pushko

Inventor： Richard W. Compans ,  Baozhong Wang ,  Beatrice Hahn ,  Weimin Liu ,  Gale Smith ,  Peter Pushko

IPC: A61K39/12 ,  A61K39/21

CPC classification number: C07K14/43572 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/03 ,  C12N9/2442 ,  C12N2710/14022 ,  C12N2740/12022 ,  C12N2740/16023 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2760/10022 ,  C12N2760/16122 ,  C12Y302/01014

Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.

Abstract translation: 本公开的实施方案包括病毒样颗粒，制备病毒样颗粒的方法，包括表达载体，其中与源自未修饰的HIV的VLPs相比，病毒样颗粒可以包含增强的衣壳结合嵌合HN-Env多肽的水平 -env多肽。 病毒样颗粒的实施方案可能具有暴露在其外表面上的Env特异性表位。 在一个实施方案中，暴露在病毒样颗粒的外表面上的Env特异性表位可以与抗HIV-Env特异性抗体特异性结合。 本公开的实施方案还包括产生对HIV-Env多肽的表位特异性的抗体的方法，包括向动物或人类递送有效量的包含嵌合HIV-Eny多肽的病毒样颗粒的悬浮液，由此 诱导对HIV-1烯多肽的表位特异的抗体的形成。

公开(公告)号：US20100330122A1

公开(公告)日：2010-12-30

申请号：US12669700

申请日：2008-07-21

Applicant: Gale Smith ,  Peter Pushko

Inventor： Gale Smith ,  Peter Pushko

IPC: A61K39/25 ,  C07K14/04 ,  A61P37/04

CPC classification number: C12N7/00 ,  A61K2039/5258 ,  C12N2710/16723 ,  Y02A50/386 ,  Y02A50/388

Abstract: The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects.

Abstract translation: 本发明公开了包含VZV糖蛋白E的新型水痘带状疱疹病毒（VZV）病毒样颗粒（VLP）。 本发明还公开了VZV-VLP的疫苗制剂和在受试者中诱导免疫应答的方法。

公开(公告)号：US07374931B2

公开(公告)日：2008-05-20

申请号：US10405871

申请日：2003-04-02

Applicant: John S. Lee ,  Peter Pushko ,  Jonathan F. Smith ,  Robert G. Ulrich

Inventor： John S. Lee ,  Peter Pushko ,  Jonathan F. Smith ,  Robert G. Ulrich

IPC: A01N43/04 ,  A01N63/00 ,  A01N65/00 ,  A61K48/00 ,  A61K31/70 ,  C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C07H21/02 ,  C07H21/04

CPC classification number: C07K14/32 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  C07K14/31 ,  C12N2799/021

Abstract: Using nucleic acids encoding mutant SEA and SEB exotoxins from Staphylococcus aureus, compositions and methods for use in inducing an immune response which is protective against staphylococcal aureus intoxication in subjects is described.

Abstract translation: 描述了使用编码来自金黄色葡萄球菌的突变体SEA和SEB外毒素的核酸，用于诱导在受试者中保护葡萄球菌金黄色葡萄球菌中毒的免疫应答的组合物和方法。

公开(公告)号：US06984504B2

公开(公告)日：2006-01-10

申请号：US10696633

申请日：2003-10-29

Applicant: Mary K. Hart ,  Julie A. Wilson ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

Inventor： Mary K. Hart ,  Julie A. Wilson ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

IPC: C12N15/40

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K16/10 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/14022 ,  C12N2760/14222 ,  C12N2770/36021 ,  C12N2770/36122 ,  C12N2770/36123 ,  C12N2770/36143 ,  C12N2770/36162

Abstract: Using the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins, a method and composition for use in inducing an immune response which is protective against infection with Ebola virus is described.

Abstract translation: 描述了使用埃博拉GP，NP，VP24，VP30，VP35和VP40病毒粒子蛋白，描述了用于诱导免疫反应的方法和组合物，该免疫应答是针对埃博拉病毒感染的。

公开(公告)号：US20130052225A1

公开(公告)日：2013-02-28

申请号：US13519948

申请日：2011-01-03

Applicant: Peter Pushko ,  Irina Tretyakova ,  Igor Lukashevich

Inventor： Peter Pushko ,  Irina Tretyakova ,  Igor Lukashevich

IPC: A61K39/12 ,  C12N7/04 ,  C12N15/85 ,  A61P37/04 ,  A61P31/14

CPC classification number: A61K39/12 ,  A61K49/0004 ,  A61K2039/5254 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/36121 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151 ,  Y02A50/383

Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

Abstract translation: 本文描述的是i-DNA TM载体和疫苗及其使用方法。 i-DNA TM在真核细胞中在体外或体内产生致病性RNA病毒特别是基孔肯雅病毒（CHIKV）的活减毒疫苗。 当将iDNA注射到疫苗接受者中时，活体减毒病毒的RNA通过受体组织中的体内转录产生。 这引发疫苗接种者组织中后代减毒病毒的产生，以及引发保护免受野生型非减毒病毒的有效免疫应答。